MET and non-small cell lung carcinoma: Recently, a novel strategy using a combination of amivantamab (EGFR/MET antibody) and lazertinib (another third-generation EGFR-TKI) [22] has paved the way to clinical approval for EGFR-mutant NSCLC, thus highlighting the need to explore NOA targets to prevent resistance to RTK-mediated inhibition.